ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ACRS vs CLYM // ALTMAN Z-SCORE & DEBT/EQUITY

Aclaris Therapeutics Inc. (NASDAQ) VS. Climb Bio Inc. (NASDAQ) • 15-METRIC TALLY: ACRS 3 — CLYM 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ACRS VS. CLYM) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ACRS CLYM SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 73.30% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -8.04% -9.19% +1.15 ACRS /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) -58.20% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity ACTIVE 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 3/9 +1.00 ACRS /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 46.1 44.9 +1.20 ACRS /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $587.3M $593.3M -$6.0M CLYM /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ACRS REV CLYM REV ACRS GROSS % CLYM GROSS % ACRS FCF CLYM FCF
FY 2025 $7.8M $0 73.3% — -$47.2M -$54.5M
FY 2024 $18.7M $0 85.1% — -$20.2M -$15.6M
FY 2023 $31.2M $0 — — -$78.3M -$20.6M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ACRS // BETA —
CLYM // BETA —